Oculis Holding AG (OCS) Long-Term Investments (2021 - 2025)
Oculis Holding AG (OCS) posted quarterly Long-Term Investments of $239.1 million for Q4 2025, up 9.61% year-over-year from $218.1 million in Q4 2024, and up 9.61% quarter-over-quarter from $218.1 million in Q4 2024.
Oculis Holding AG (OCS) Long-Term Investments (2021 - 2025) Analysis & Trends
Oculis Holding AG's Long-Term Investments history runs 5 years deep, the most recent figure standing at $239.1 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 9.61% year-over-year to $239.1 million; the TTM figure through Dec 2025 stood at $239.1 million (up 9.61% YoY), while the FY2025 annual figure was $230.5 million, up 6.11% from the prior year.
- Long-Term Investments for Q4 2025 stood at $239.1 million, up from $218.1 million in the prior quarter.
- The five-year high for Long-Term Investments was $239.1 million in Q4 2025, with the low at $51901.1 in Q4 2022.
- The 5-year median for Long-Term Investments is $215.4 million (2023), against an average of $134.5 million.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments declined 7.97% in 2022, then soared 414920.6% in 2023.
- Oculis Holding AG's Long-Term Investments stood at $56394.1 in 2021, then decreased by 7.97% to $51901.1 in 2022, then jumped by 414920.6% to $215.4 million in 2023, then rose by 1.26% to $218.1 million in 2024, then increased by 9.61% to $239.1 million in 2025.
- Business Quant data shows OCS's Long-Term Investments at $239.1 million in Q4 2025, $218.1 million in Q4 2024, and $215.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 239.06 Mn |
| Dec 31, 2024 | 218.11 Mn |
| Dec 31, 2023 | 215.40 Mn |
| Dec 31, 2022 | 51,901.10 |
| Dec 31, 2021 | 56,394.11 |